Gilead Sciences Inc. (GILD)

Statement of Financial Position, Assets

Difficulty: Beginner

Annual Data

Quarterly Data

The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Gilead Sciences Inc., Consolidated Statement of Financial Position, Assets

USD $ in millions

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Cash and cash equivalents	7,588	8,229	12,851	10,027	2,113
Short-term marketable securities	17,922	3,666	1,756	101	19
Accounts receivable, net of allowances	3,851	4,514	5,854	4,635	2,100
Inventories	801	1,587	1,955	1,386	2,056
Deferred tax assets	–	857	828	508	331
Prepaid and other current assets	1,661	1,592	1,519	1,057	656
Current assets	31,823	20,445	24,763	17,714	7,274
Property, plant and equipment, net	3,295	2,865	2,276	1,674	1,166
Long-term marketable securities	11,184	20,485	11,601	1,598	439
Intangible assets, net	17,100	8,971	10,247	11,073	11,900
Goodwill	4,159	1,172	1,172	1,172	1,169
Other long-term assets	2,722	3,039	1,780	1,433	549
Noncurrent assets	38,460	36,532	27,076	16,950	15,223
Total assets	70,283	56,977	51,839	34,664	22,497

Source: Gilead Sciences Inc., Annual Reports

Item	Description	The company
Cash and cash equivalents	Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents.	Gilead Sciences Inc.'s cash and cash equivalents declined from 2015 to 2016 and from 2016 to 2017.
Short-term marketable securities	Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.	Gilead Sciences Inc.'s short-term marketable securities increased from 2015 to 2016 and from 2016 to 2017.
Accounts receivable, net of allowances	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Gilead Sciences Inc.'s accounts receivable, net of allowances declined from 2015 to 2016 and from 2016 to 2017.
Inventories	Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).	Gilead Sciences Inc.'s inventories declined from 2015 to 2016 and from 2016 to 2017.
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Gilead Sciences Inc.'s current assets declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
Property, plant and equipment, net	Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment.	Gilead Sciences Inc.'s property, plant and equipment, net increased from 2015 to 2016 and from 2016 to 2017.
Noncurrent assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Gilead Sciences Inc.'s noncurrent assets increased from 2015 to 2016 and from 2016 to 2017.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Gilead Sciences Inc.'s total assets increased from 2015 to 2016 and from 2016 to 2017.